What Diclofenaco Cinfa treats: main uses and benefits

Diclofenaco Cinfa is a medication belonging to the group known as non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to reduce inflammation and manage pain associated with various physical conditions.

Main Therapeutic Uses

The medication is indicated for the symptomatic treatment of several conditions characterized by pain and inflammation, including:

• Chronic Inflammatory Arthritis: Management of symptoms in conditions such as rheumatoid arthritis and ankylosing spondylitis.
• Degenerative Joint Disease: Relief of pain and inflammation caused by osteoarthritis and various types of arthrosis.
• Acute Rheumatic Conditions: Treatment of gout attacks and acute musculoskeletal disorders, such as tendonitis, tenosynovitis, and bursitis.
• Post-Traumatic and Post-Operative Pain: Management of inflammation and pain following injuries (such as sprains or strains) or surgical procedures.
• Gynecological Pain: Relief of symptoms in cases of primary dysmenorrhea (menstrual pain) and other inflammatory processes in the pelvic area.

Benefits of Treatment

The pharmacological action of Diclofenaco Cinfa provides several clinical benefits focused on improving a patient's physical comfort and functionality:

• Reduction of Inflammation: By inhibiting the synthesis of prostaglandins—substances in the body that signal pain and trigger inflammation—the medication helps decrease swelling in the affected tissues.
• Pain Relief: It acts as an analgesic, addressing mild to moderate pain levels associated with both acute injuries and chronic inflammatory states.
• Improvement in Mobility: By reducing joint stiffness and swelling caused by inflammatory processes, the medication can help restore a better range of motion in patients with rheumatic or degenerative conditions.
• Fever Reduction: Although not its primary use, it possesses antipyretic properties that can help lower body temperature when fever accompanies an inflammatory process.

Regulatory References

1. NIH StatPearls overview

Who Can and Cannot Use Diclofenaco Cinfa? — Official Regulatory Information

Population eligibility for Diclofenaco Cinfa (Diclofenac) is defined by strict regulatory criteria, primarily based on contraindications related to cardiovascular health, gastrointestinal integrity, and physiological state.

---

Absolute Contraindications (Must Not Use)

Use is contraindicated for patients with:

• Known hypersensitivity to diclofenac or any NSAID that causes asthma, urticaria, or angioedema.
• Active gastrointestinal ulceration, bleeding, or perforation, or a history of GI bleeding related to prior NSAID use.
• Established severe cardiovascular disease, including Congestive Heart Failure (NYHA Class II–IV), ischemic heart disease, or cerebrovascular disease.
• Severe hepatic or severe renal failure.
• Treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• The third trimester of pregnancy (from 30 weeks gestation).

---

Eligibility by Age and Condition

Population Group	Regulatory Eligibility Status
Pediatric (Under 14 years)	Generally not recommended for oral tablet forms.
Geriatric (Older Adults)	Requires caution and close monitoring due to increased risk of adverse events.
Mild-to-Moderate Organ Impairment	Requires caution and close monitoring (e.g., mild-to-moderate hepatic or renal impairment).
Pregnancy (20–30 weeks)	Restricted use; avoid unless the clinical benefit outweighs the risk.

Eligibility for adult use is standard, provided no absolute contraindications exist. Conditional use requires treatment to be limited to the lowest effective dosage for the shortest possible duration.

Interactions with other medicines and products

The official interaction profile of Diclofenaco Cinfa is structured around specific Pharmacodynamic (PD) risks and Pharmacokinetic (PK) modifications as documented in regulatory labels.

---

Contraindicated Combinations and PD Risks

Diclofenac is contraindicated for the management of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin, is not recommended due to a documented additive PD risk of gastrointestinal bleeding. Use with Anticoagulants (e.g., Warfarin) or SSRIs also increases the official risk of hemorrhage. Consumption of alcohol or concurrent tobacco use carries a specific, officially noted risk of serious gastric hemorrhage.

---

Exposure Modification and Administration

Co-administration with strong CYP2C9 inhibitors, such as Voriconazole, officially results in a significant increase in Diclofenac plasma exposure (Cmax and AUC). Diclofenac may also increase the serum concentration of co-administered drugs like Digoxin and Lithium. A PD interaction exists with Antihypertensives (ACE Inhibitors, ARBs) and Diuretics, as Diclofenac may diminish their effects. This combination presents a heightened, officially noted risk of renal function deterioration in elderly or renally impaired patients. Furthermore, specific oral forms (solutions/capsules) require administration on an empty stomach to ensure proper PK characteristics.

Primary Action: Cyclooxygenase (COX) Inhibition

Diclofenaco Cinfa primarily acts within the eicosanoid synthesis pathways by inhibiting the cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2 isoforms. These enzymes are the key biological targets responsible for initiating the creation of prostaglandins from arachidonic acid. This fundamental mechanism reduces the resulting activity of these chemical mediators, which modulate cellular and vascular responses.

---

Modulating Sensitization Cascades

Suppression of prostaglandin synthesis initiates a downstream mechanistic cascade that affects systems mediating peripheral sensitization and thermoregulation. Prostaglandins function as neuro-sensitizers; their diminished production prevents the lowering of the firing threshold of peripheral nerve endings (nociceptors). This pathway adjustment results in altered signaling dynamics and reduced neuronal hypersensitivity, which constitutes the mechanistic basis of the drug's effect.

---

Influence on Signaling Dynamics

The mechanism engages systems characterized by elevated inflammatory mediator presence, causing a modulation of signaling intensity. By reducing the overall local concentration of sensitizing agents, the compound alters the signaling dynamics in peripheral neural and vascular pathways. The resulting action influences the threshold and magnitude of nociceptive and vascular responses.

How to Use Diclofenaco Cinfa: Official Administration Guidelines

The usage of diclofenac, the active component of this medication, is structured by a set of official instructions that dictate the method, dose, and frequency of administration, strictly adhering to the principle of using the lowest effective dose for the shortest duration possible.

---

Official Administration Parameters

Instruction Entity	Labeled Usage Requirement
Route and Form	Approved administration includes Oral (tablets, solution), Parenteral (IM/IV), Rectal, and Topical (gels) forms.
Dosing Schedule	Oral daily doses for chronic conditions like Rheumatoid Arthritis typically range from 150 mg to 200 mg per day, administered in divided doses. The maximum intravenous dose for acute pain is limited to 150 mg per day.
Frequency	Ranges from once daily (extended-release tablets) to every 6 hours as needed for certain parenteral applications.
Timing with Meals	Immediate-release oral powder for acute symptoms should be taken on an empty stomach. Delayed-release forms may be taken with food to assist tolerance.

---

Procedural and Population-Specific Conditions

Administration requires specific steps depending on the formulation. Delayed-release tablets must be swallowed whole and must not be crushed, split, or chewed, as this compromises the intended release profile. For older adults, the official guidance requires the use of the lowest effective dosage to be initiated. Furthermore, most adult oral preparations are not indicated for use in the pediatric population.

Research Evidence / Overview of Studies for Diclofenaco Cinfa

This overview describes the types of clinical studies that have been conducted on this compound and what kind of information the research provides. It is a neutral summary of the evidence landscape and does not offer clinical advice or personal recommendations.

---

Research Evidence for Musculoskeletal and Inflammatory Conditions

Research on this compound was evaluated in settings addressing conditions marked by functional limitations such as osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). The research base for these indications relates to numerous Randomized Controlled Trials (RCTs), frequently synthesized in comprehensive Systematic Reviews and pooled analyses.

These studies were used in research exploring how symptoms change over time. Researchers monitored patient-reported outcomes describing perceived discomfort and examined various measures of function, such as mobility and stiffness scores. Findings describe patterns observed in the studies related to various administered dose levels. For some indications, the evidence quality varies across studies when pooling results from different trials, leading to reported instances of heterogeneity (variability in results).

---

Research Evidence for Acute and Episodic Pain

Research also examined the compound's use in conditions characterized by fluctuating or episodic manifestations, such as acute pain from sources like sprains, strains, post-operative discomfort, and primary dysmenorrhea (menstrual cramps). These trials often involved research exploring short-term symptom changes and were conducted during periods of increased symptom activity.

The research focused heavily on time-based outcomes related to physical discomfort, specifically exploring the measured time to onset of an observed effect and the reported duration of that effect. Data show patterns related to the temporary nature of the observed symptomatic change, with findings consistently limited to the immediate symptomatic period following the acute event.

---

Long-Term Studies and Follow-up

Clinical trials for this compound monitored its use over defined time intervals that include both short-term (days to weeks) and mid-term (up to a few months) periods. These periods allow researchers to report how symptoms evolved in the observed populations during the study window.

Research is still ongoing; comprehensive data related to continuous use over many months or years are not fully established, particularly for chronic conditions like RA or OA. There is limited information for long-term outcomes that track the stability of the observed effects and patient experience beyond the initial study periods.

---

Evidence in Special Populations

Research examined the use of the compound in specific populations. For instance, some evidence was observed in older adults with degenerative joint disease, and other research examined adolescents experiencing specific inflammatory symptoms (e.g., Juvenile Rheumatoid Arthritis).

However, data for certain groups remain insufficient. This includes populations with complex or multiple coexisting health issues (comorbidities) and specific physiological states, such as those who are pregnant. The results apply only to the populations studied in the specific clinical trials.

---

What Is Still Uncertain About Diclofenaco Cinfa Research

Evidence highlights what is known — and what is still uncertain regarding the compound's research base. Data are still emerging for several areas, and research provides context but does not predict whether an individual will respond similarly to the group findings.

For many of the studied indications, the follow-up durations were limited to short or intermediate periods, meaning comprehensive data on outcomes over several years are not fully established. Subgroup findings are uncertain when analyzing the data for specific populations within the larger studied groups, and evidence quality varies across studies due to differences in design or sample size. Because study results reflect the specific conditions under which they were conducted, the research provides context but does not predict whether an individual will respond similarly to the group findings.

Key Studies & References

1. Diclofenac. NIH StatPearls Overview

Common questions about Diclofenaco Cinfa (FAQ)

Q: What is Diclofenaco Cinfa used for?

A: Diclofenaco Cinfa is used to relieve pain and inflammation. It is a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is commonly prescribed to treat conditions such as:

• Osteoarthritis (a type of arthritis that affects the joints).
• Rheumatoid arthritis (a chronic inflammatory disorder affecting the joints).
• Ankylosing spondylitis (a type of arthritis that affects the joints in the spine).
• Other painful conditions, like menstrual cramps.

Q: How does Diclofenaco Cinfa work?

A: Diclofenaco Cinfa works by blocking the body’s production of certain substances (prostaglandins) that cause inflammation, pain, and fever. By reducing the levels of these substances, it helps to decrease swelling and pain.

Q: What should I know about taking Diclofenaco Cinfa with other medications?

A: It is important to tell your doctor or pharmacist about all other medications you are taking, including over-the-counter medicines and herbal supplements, as some can interact with Diclofenaco Cinfa. Significant interactions can occur with:

• Other NSAIDs or aspirin: Taking these together can increase the risk of stomach bleeding and ulcers.
• Blood thinners (anticoagulants): The risk of bleeding may be increased.
• High blood pressure medicines: Diclofenaco Cinfa may reduce the effectiveness of these drugs.
• Diuretics (water pills): Taking these with Diclofenaco Cinfa may affect kidney function.

Your doctor will determine if the combination is safe for you.

Q: What are the possible serious side effects of Diclofenaco Cinfa?

A: Although not everyone experiences them, Diclofenaco Cinfa carries a risk of serious side effects. These include:

• Cardiovascular risks: An increased risk of serious events like heart attack and stroke, especially with higher doses or long-term use, and in patients with existing heart problems.
• Gastrointestinal risks: A risk of stomach bleeding and ulcers, which can be serious and sometimes fatal. This risk is higher in the elderly.
• Liver and kidney problems.
• Serious skin reactions.

If you experience any signs of a serious reaction, such as chest pain, sudden weakness, black or tarry stools, or severe allergic reactions (e.g., swelling of the face, difficulty breathing), seek emergency medical attention immediately.

Q: Can I take Diclofenaco Cinfa if I have a history of heart disease or stroke?

A: Diclofenaco Cinfa should be used with caution if you have a history of heart disease, heart failure, or stroke, as it may worsen these conditions and increase the risk of cardiovascular events. For this reason, your doctor will likely prescribe the lowest effective dose for the shortest possible duration.

Q: Is Diclofenaco Cinfa safe for people with severe kidney disease?

A: No, Diclofenaco Cinfa should not be used in patients with severe kidney disease. NSAIDs can affect blood flow to the kidneys and potentially worsen existing severe kidney issues. Dehydration or hypovolemia (low blood volume) must also be corrected before using this medicine.

Q: How long can I take Diclofenaco Cinfa for?

A: Diclofenaco Cinfa is not generally intended for long-term use, and you should not use it more often or for a longer time than your doctor ordered. The goal is often to use the lowest effective dose for the shortest duration necessary to control symptoms. It is important to follow your doctor’s specific instructions for the length of your treatment.

Storage Requirements

Diclofenaco Cinfa tablets must be stored at a temperature below 25 C to ensure stability and preserve the integrity of the product. The tablets should be kept out of the sight and reach of children as a primary safety measure. Storage must be in the original, properly labeled containers under conditions that provide protection from moisture.

---

Disposal Instructions

Unused or expired Diclofenaco Cinfa must be disposed of according to local and national regulations to avoid environmental contamination. The most reliable method is utilizing an official drug take-back program at a pharmacy or authorized collection site. Disposal practices must ensure the product avoids release to the environment or sewage system.